Edwards Lifesciences Co. (NYSE:EW) SVP Wayne Markowitz Sells 268 Shares

Edwards Lifesciences Co. (NYSE:EW) SVP Wayne Markowitz sold 268 shares of the firm’s stock in a transaction that occurred on Wednesday, May 7th. The stock was sold at an average price of $75.08, for a total transaction of $20,121.44. Following the sale, the senior vice president now owns 9,299 shares in the company, valued at approximately $698,168.92. This trade represents a 2.80 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Edwards Lifesciences Stock Down 1.1 %

NYSE EW opened at $73.82 on Friday. The stock has a market cap of $43.40 billion, a PE ratio of 10.59, a P/E/G ratio of 4.82 and a beta of 1.12. The business has a 50 day moving average price of $71.48 and a two-hundred day moving average price of $71.50. Edwards Lifesciences Co. has a fifty-two week low of $58.93 and a fifty-two week high of $95.25. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share for the quarter, beating analysts’ consensus estimates of $0.60 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. The business had revenue of $1.41 billion during the quarter, compared to analyst estimates of $1.40 billion. During the same period last year, the business earned $0.66 EPS. The business’s revenue was up 6.2% on a year-over-year basis. As a group, sell-side analysts predict that Edwards Lifesciences Co. will post 2.45 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the company. Evercore ISI decreased their price objective on Edwards Lifesciences from $75.00 to $73.00 and set an “in-line” rating on the stock in a report on Wednesday, February 12th. Canaccord Genuity Group raised their price target on Edwards Lifesciences from $71.00 to $75.00 and gave the stock a “hold” rating in a research note on Friday, April 25th. Barclays upped their price objective on shares of Edwards Lifesciences from $88.00 to $90.00 and gave the company an “overweight” rating in a research note on Thursday, February 13th. Truist Financial decreased their target price on shares of Edwards Lifesciences from $78.00 to $75.00 and set a “hold” rating on the stock in a research report on Friday, April 11th. Finally, StockNews.com raised shares of Edwards Lifesciences from a “hold” rating to a “buy” rating in a research note on Thursday. One equities research analyst has rated the stock with a sell rating, twelve have given a hold rating and twelve have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $79.45.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. Prosperity Consulting Group LLC increased its holdings in Edwards Lifesciences by 3.6% during the 4th quarter. Prosperity Consulting Group LLC now owns 3,906 shares of the medical research company’s stock worth $289,000 after purchasing an additional 134 shares during the last quarter. Arlington Trust Co LLC increased its stake in shares of Edwards Lifesciences by 1.2% in the first quarter. Arlington Trust Co LLC now owns 11,092 shares of the medical research company’s stock worth $804,000 after buying an additional 135 shares during the last quarter. Abacus Planning Group Inc. raised its holdings in Edwards Lifesciences by 0.3% in the fourth quarter. Abacus Planning Group Inc. now owns 40,207 shares of the medical research company’s stock valued at $2,977,000 after acquiring an additional 140 shares in the last quarter. Valeo Financial Advisors LLC boosted its stake in Edwards Lifesciences by 2.8% during the 1st quarter. Valeo Financial Advisors LLC now owns 5,136 shares of the medical research company’s stock valued at $372,000 after acquiring an additional 142 shares during the last quarter. Finally, Versant Capital Management Inc increased its position in shares of Edwards Lifesciences by 9.3% in the 1st quarter. Versant Capital Management Inc now owns 1,698 shares of the medical research company’s stock worth $123,000 after purchasing an additional 145 shares during the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.